Law firm probes ADMA Biologics' leadership for possible breaches of fiduciary duty to shareholders

Bernstein Liebhard LLP is investigating whether certain directors and officers of ADMA Biologics, Inc. breached their fiduciary duties to the company and its shareholders. The probe aims to determine if the leadership acted in shareholders' best interests and if legal action is warranted. Current ADMA shareholders who bought shares before August 9, 2024, are encouraged to contact the firm for a confidential consultation about their legal rights. This investigation could lead to legal remedies if breaches are confirmed, impacting shareholder value and corporate governance at ADMA Biologics.